Skip to main content
OpenTrials
Completed

NCT Number: NCT05040750

Correlation Between Cardiac Markers and Severity of COVID-19

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiac Event Cardiovascular Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University

Cairo, 69711, Egypt

About this study

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to >11.8 million confirmed cases with >545000 deaths worldwide by July 9, 2020 Patients with preexisting cardiovascular conditions are particularly at risk and have poor prognosis data suggest that cardiac injury, manifested by cardiac biomarker elevation, is detected in a sizable of COVID-19 patients and is associated with adverse outcomes and increased mortality. However, how useful cardiac biomarkers are in COVID-19 prognosis and how to utilize these markers have not been well defined The study will include all moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. The primary outcome is the relation between cardiac markers and mortality rate in critically ill COVID 19 patients The secondary outcome is the relationship between cardiac and inflammatory and coagulation markers

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all moderate to severe COVID 19 patients who were admitted to ICU.
  • Both genders
  • age group 18-60 years

Exclusion criteria

  • a refusal to participate in the study,
  • pregnant patients,
  • patients aged <18 or >60. years,
  • recent history of acute myocardial infarction (< 1 month before admission).

Treatment and study plan

laboratory investigation

Other

observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients

Primary outcomes

  1. relation between cardiac markers and mortality rate in critically ill COVID 19 patients

    Time frame: 4 month

    relate cardiac biomarkers to mortality rate

Secondary outcomes

  1. relation ship between cardiac and inflammatory and coagulation markers

    Time frame: 4 month

    compare cardiac markers to inflammatory and coagulation laboratory findings

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Correlation Between Cardiac Markers and Severity of COVID-19 in Egyptian Population

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Sep 10, 2021
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.